会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • PHOSPHAPLATINS AND THEIR USE IN THE TREATMENT OF CANCERS RESISTANT TO CISPLATIN AND CARBOPLATIN
    • 磷酸钙及其在治疗抗癌药和卡波品的癌症中的应用
    • US20110313182A1
    • 2011-12-22
    • US13221458
    • 2011-08-30
    • Rathindra N. Bose
    • Rathindra N. Bose
    • C07F9/08
    • C07F15/0086A61K31/6615A61K31/663A61K31/665A61K33/24
    • The present invention provides phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.
    • 本发明提供了磷酸铂蛋白,铂(II)和(IV)的稳定的分离的单体磷酸复合物及其用于治疗癌症的方法,包括顺铂和卡铂耐药性癌症。 与顺铂不同,这些复合物不容易经历水解,并且在水溶液中是非常可溶的和稳定的。 此外,这些复合物 - 不像顺铂,卡铂和相关的铂类抗癌剂 - 不结合DNA。 相反,数据表明磷酸蛋白酶引发fas和fas相关转录因子的过度表达以及一些促细胞凋亡基因如Bak和Bax。 然而,复合物对癌细胞表现出巨大的细胞毒性。 因此,本发明提供了与本领域相比具有不同分子靶标的新型铂抗癌剂。